Loading
institutionsInstitution
Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Lausanne's university hospital and Ludwig branch, home of the temozolomide glioblastoma trial, Solange Peters and a leading personalised T-cell therapy programme.
Also called: CHUVCentre hospitalier universitaire vaudoisSwiss Cancer Center LémanAGORA Cancer Research Center
Overview
The CHUV Department of Oncology, headed by Solange Peters (ESMO president 2020-2021), works with the Ludwig Institute for Cancer Research Lausanne branch under George Coukos, the University of Lausanne, EPFL's ISREC institute and the Geneva hospitals within the Swiss Cancer Center Léman, housed in the AGORA research building opened in 2018. Roger Stupp led from Lausanne the EORTC/NCIC trial that made radiotherapy plus temozolomide the standard for glioblastoma, and Douglas Hanahan, author of 'The Hallmarks of Cancer', directed ISREC. The Ludwig groups run personalised tumour-infiltrating lymphocyte and neoantigen-targeted T-cell trials in ovarian and other cancers, and the hospital is a major thoracic oncology and immunotherapy trial site with a phase 1 unit.
Location
Lausanne, CH
Type
hospital · Université de Lausanne
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#181 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Centre Hospitalier Universitaire Vaudois, including child institutions. 838 works · 14,951 citations · 83% open access · 13% clinical trials · 5% reviews.
Oncology works per year
1772022
1662023
1722024
2022025
1212026
Most works
- Solange Peters147 works
- George Coukos43 works
- Olivier Alain Michielin38 works
- John B.A.G. Haanen36 works
- Michel Obéid32 works
- Manuela Eicher32 works
- Khalil Zaman26 works
- Melissa Lynne Johnson22 works
- Krisztián Homicskó21 works
- Martin Reck20 works
Most cited
- Ludwig Lausanne immuno-oncology
- Personalised TIL and T-cell therapy
- Thoracic oncology
- Neuro-oncology heritage
- Swiss Cancer Center Léman
Jean Bourhis
Head of Radiation Oncology, Lausanne University Hospital (CHUV)
Head and neck radiotherapyMeta-analysisAltered fractionation
Radiation oncologist behind the MACH-NC meta-analyses that proved chemoradiotherapy helps head and neck cancer, and the first FLASH-treated patient.
Marie-Catherine Vozenin
Head of the Radiotherapy and Radiobiology Laboratory, Geneva University Hospitals; Professor, University of Geneva
FLASH radiotherapyRadiobiologyNormal tissue protection
Radiobiologist who discovered the FLASH effect: ultra-fast radiation spares healthy tissue while still killing tumours.
Monika E. Hegi
Professor and Head of the Laboratory of Brain Tumor Biology and Genetics, Lausanne University Hospital (CHUV)
GlioblastomaMGMT methylationTumour biomarkers
Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for.
Solange Peters
Head of Medical Oncology, Lausanne University Hospital (CHUV); ESMO President 2020-2021
Thoracic oncologyImmunotherapyMesothelioma
Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.
Roger Stupp
Professor of Neurological Surgery and Neurology, Northwestern University; formerly Lausanne and EORTC
Neuro-oncologyGlioblastomaTumour treating fields
Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.
Similar pages
- TrialEORTC 26981 / NCIC CE.3 (Stupp trial)
Shares Monika E. Hegi, Roger Stupp, EORTC, Glioma & glioblastoma.
- PersonYardena Samuels
Shares TIL therapy, Neoantigen, Personalised neoantigen (mRNA) vaccines, Melanoma.
- Key paperStupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma
Shares Monika E. Hegi, Roger Stupp, EORTC, Glioma & glioblastoma.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
- PersonTimothy A. Chan
Shares Neoantigen, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Shares Personalised neoantigen (mRNA) vaccines, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
- TrialTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Shares TCR-T cell therapy, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Personalised neoantigen (mRNA) vaccines, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
cancers
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)